Suppr超能文献

利用社交媒体数据了解阿尔茨海默病患者就医过程中的障碍

Understanding Barriers Along the Patient Journey in Alzheimer's Disease Using Social Media Data.

作者信息

Tahami Monfared Amir Abbas, Stern Yaakov, Doogan Stephen, Irizarry Michael, Zhang Quanwu

机构信息

Eisai, Inc., 200 Metro Blvd, Nutley, NJ, 07110, USA.

Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.

出版信息

Neurol Ther. 2023 Jun;12(3):899-918. doi: 10.1007/s40120-023-00472-x. Epub 2023 Apr 15.

Abstract

INTRODUCTION

We speculated that social media data from Alzheimer's disease (AD) stakeholders (patients, caregivers, and clinicians) could identify barriers along the patient journey in AD, and that insights gained may help devise strategies to remove barriers, and ultimately improve the patient journey.

METHODS

Our sample was drawn from a repository of social media posts extracted from 112 public sources between January 1998 and December 2021 using natural language processing text-mining algorithms. The patient journey was classified into three phases: (1) early signs/experiences (Early Signs); (2) screening/assessment/diagnosis (Screening); and (3) treatment/management (Treatment). In the Early Signs phase, issues/challenges derived from a conceptual AD identification framework (ADIF) were examined. In subsequent phases, behavioral/psychiatric challenges, access/barriers to health care, screening/diagnostic methods, and symptomatic treatments for AD were identified. Posts were classified by AD stakeholder type or disease stage, if possible.

RESULTS

We identified 225,977 AD patient journey-related social media posts. Anxiety was a predominant issue/challenge in all patient journey phases. In the Screening and Treatment phases combined, access/barriers to care were described in 16% of posts; unwillingness/resistance to seeking care was a major barrier (≥ 75% of access-related posts across all stakeholders). Commonly identified structural barriers (e.g., affordability/cost, geography/transportation/distance) were more common in patient/caregiver posts than clinician posts. Among Screening-related posts, imaging/scans were commonly mentioned by all stakeholders; biomarkers were more commonly mentioned by patients than clinicians. Treatment-related concerns were identified in 17% of stakeholder-specified posts that named pharmacological agents/classes for the symptomatic management of AD.

CONCLUSION

This descriptive analysis of out-of-clinic experiences reflected in AD social media posts found that unwillingness/resistance to seeking care was a key barrier, followed by structural barriers to health care, such as affordability/cost. Insights from the lived experiences of AD stakeholders are valuable and highlight the need to improve the patient journey in AD and ease patient and caregiver burden.

摘要

引言

我们推测,来自阿尔茨海默病(AD)利益相关者(患者、护理人员和临床医生)的社交媒体数据能够识别AD患者就医过程中的障碍,并且所获得的见解可能有助于制定消除障碍的策略,最终改善患者就医体验。

方法

我们的样本来自于1998年1月至2021年12月期间使用自然语言处理文本挖掘算法从112个公共来源提取的社交媒体帖子库。患者就医过程分为三个阶段:(1)早期症状/经历(早期症状);(2)筛查/评估/诊断(筛查);以及(3)治疗/管理(治疗)。在早期症状阶段,研究了源自概念性AD识别框架(ADIF)的问题/挑战。在随后的阶段,识别了行为/精神方面的挑战、医疗保健的可及性/障碍、筛查/诊断方法以及AD的对症治疗。如果可能,帖子按AD利益相关者类型或疾病阶段进行分类。

结果

我们识别出225,977条与AD患者就医过程相关的社交媒体帖子。焦虑是所有患者就医阶段的主要问题/挑战。在筛查和治疗阶段合计,16%的帖子描述了医疗保健的可及性/障碍;不愿/抗拒寻求医疗是主要障碍(在所有利益相关者中,≥75%与可及性相关的帖子)。常见的结构性障碍(如可承受性/成本、地理位置/交通/距离)在患者/护理人员的帖子中比临床医生的帖子中更常见。在与筛查相关的帖子中,所有利益相关者都普遍提到了成像/扫描;患者比临床医生更常提到生物标志物。在17%指定了用于AD对症管理的药物制剂/类别的利益相关者特定帖子中发现了与治疗相关的担忧。

结论

这项对AD社交媒体帖子中反映的门诊外经历的描述性分析发现,不愿/抗拒寻求医疗是一个关键障碍,其次是医疗保健的结构性障碍,如可承受性/成本。AD利益相关者的实际生活经历所提供的见解很有价值,并凸显了改善AD患者就医体验以及减轻患者和护理人员负担的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eebb/10195971/36556e1b5326/40120_2023_472_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验